BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chromos Molecular Systems Inc. (CHR.TO) Enters into Loan and Lending Arrangements


3/21/2008 7:12:28 AM

BURNABY, BC, March 20 /PRNewswire-FirstCall/ - Chromos Molecular Systems Inc. ("Chromos") announced today that the Company entered into a secured, convertible debenture agreement to borrow $400,000. The proceeds of the loan are to be used to fund expenses associated with the preparation of delinquent continuous disclosure documents and maintaining the integrity of the remaining assets of the Company. The principal and interest, at 12% per annum, are due and payable on June 30, 2008. The debenture holder has the right, upon notice, to convert all or part of the principal and unpaid interest into common shares of the Company at the conversion price of $0.03 per share. The Company also entered into a Pledge of Securities agreement as part of the security arrangement with the debenture holder for the Company's common shares in Agrisoma Biosciences Inc. ("Agrisoma"). As collateral for the convertible debenture, the Company provided the debenture holder a general security agreement providing a charge over all the Company's assets. Prior to entering into this transaction, the Company obtained a partial revocation of the existing cease trade order from the B.C. Securities Commission.

The Company has also entered into a convertible promissory note agreement (the "Agrisoma Note") to loan $500,000 to Agrisoma. Of this amount, $118,000 was funded in-kind by Chromos by offsetting it against $118,000 of amounts due from Agrisoma for license fees, rent and other services, and patent cost recoveries. The remaining $382,000 was funded in cash by Chromos to Agrisoma. The cash advanced to Agrisoma is to be used for operations. The secured Agrisoma Note, which bears interest of 15% per annum, is due the earlier of: June 30, 2008 and certain specified events. As collateral for the Agrisoma Note, Agrisoma provided the Company with a general security agreement providing a charge over all of Agrisoma's assets.

Risks and Uncertainties

Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Chromos, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

To the extent possible, management implements strategies to reduce or mitigate the risks and uncertainties associated with Chromos' operations. Operating risks include (i) the continued availability of capital to finance Chromos' activities; (ii) Chromos' limited cash position, and (iii) Chromos' limited operations.

CONTACT: Jeff Charpentier, Vice President, Finance and CFO, Tel: (604) 415-7132, Email:jcharpentier@chromos.com; Alistair Duncan, President & CEO, Tel: (604) 415-7121, Email: aduncan@chromos.com, Website: www.chromos.com

CONTACT: Jeff Charpentier, Vice President, Finance and CFO, Tel: (604)
415-7132, Email:jcharpentier@chromos.com; Alistair Duncan, President & CEO,
Tel: (604) 415-7121, Email: aduncan@chromos.com, Website: www.chromos.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES